Name |
Purpose |
For People with |
Our location(s) |
More Info |
Study Type |
Status |
CAMBRIA-2 |
To compare the effectiveness and safety of camizestrant (AZD9833), a new oral medication that targets estrogen receptors, with standard hormone therapies. |
Early-stage breast cancer that is hormone receptor-positive and HER2-negative, and who have a higher risk of cancer returning. |
MMUH & MPH & SVUH |
(opens in a new window)Click here |
Medicinal Trial |
Open |
Destiny 15 |
Evaluate the effectiveness of Trastuzumab Deruxtecan (T-DXd) in delaying disease progression. |
People with HER2-low or HER2 Immunohistochemistry (IHC) 0 breast cancer, whose disease is untreatable by surgery or is metastatic. |
SVUH |
(opens in a new window)Click here |
Medicinal Trial |
Open |
EXPERT |
Evaluate whether women who are at low risk (determined from genetic testing) can safely avoid post-surgery radiotherapy. |
Female patients aged ≥50 years with HR-positive and HER2-negative early stage breast cancer. |
SVUH & MMUH via St Luke’s Radiation Oncology Network |
(opens in a new window)Click here |
Radiotherapy Trial |
Open |
FourLight-3 (C4391024) |
To compare the effectiveness of: A) PF-07220060 plus Letrozole, against b) CDK4/6 inhibitor plus Letrozole |
Hormone receptor (HR)-positive, HER2-negative advanced/metastatic breast cancer who have not received any prior systemic anti-cancer treatment for advanced/metastatic disease |
SVUH & MMUH & MPH |
(opens in a new window)Click here |
Medicinal Trial |
Open |
Treat ctDNA |
Elacestrant for treating ER+/HER2- |
Breast cancer patients with ctDNA relapse |
MMUH & MPH |
(opens in a new window)Click here |
Medicinal trial |
Open |
J2J-MC-JZLH (Ember 4) |
Study of adjuvant Imlunestrant vs standard adjuvant endocrine therapy |
Previously received 2 to 5 years of adjuvant endocrine therapy for ER+, HER2- early breast cancer with an increased risk of recurrence |
SVUH |
(opens in a new window)Click here |
Medicinal Trial |
Open |
MK-2870-010 |
To compare the effectiveness of the drug MK-2870 (alone or combined with Pembrolizumab) against standard treatment of physician’s choice. |
People with HR+/HER2- advanced or metastatic breast cancer, which cannot be removed with surgery. |
SVUH & MMUH |
(opens in a new window)Click here |
Medicinal Trial |
Open |
Merck MK-2870-012 |
To compare the efficacy and safety of a) adjuvant MK-2870 plus Pembrolizumab against b) treatment of physician’s choice. |
People with Triple-Negative Breast Cancer who received neoadjuvant therapy that was not fully effective. |
SVUH |
(opens in a new window)Click here |
Medicinal Trial |
Open |
Ovarian Escape |
To determine how common is 'ovarian escape' in women receiving ovarian function suppression |
Premenopausal women receiving ovarian function suppression and endocrine therapy for early-stage and metastatic hormone receptor- positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer |
SVUH & MMUH |
NA |
Translational study |
Open |
Shamrock |
To examine the effectiveness of the drug trastuzumab deruxtecan (T-DXd) |
People with HER2-positive breast cancer (stage 2 or 3) |
SVUH |
(opens in a new window)Click here |
Medicinal Trial |
On hold |
SIGNATURE Study (RS21 036) |
To explore the potential use of exosomes, isolated from the blood of patients diagnosed with TNBC (triple negative breast cancer), as a personal biomarker for the individual. |
People with triple negative breast cancer |
SVUH |
NA |
Translational Study |
Open |
ASCENT 05 |
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice. |
Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy |
MMUH |
TBD |
Medicinal Trial |
Open |
TAORMINA |
To investigate if the addition of stereotactic ablative radiotherapy (SABR) to the oligometastatic sites in addition to the standard first-line treatment can improve progression-free survival (PFS). |
Patients with oligometastatic breast cancer (OMBC) that will be allocated to combined stereotactic ablative radiotherapy (SABR) + systemic therapy |
SVUH via via St Luke’s Radiation Oncology Network |
(opens in a new window)Click here |
Radiotherapy Trial |
Open |
ATNEC |
To assess if omitting further axillary treatment (ALND and ART) is non-inferior to axillary treatment in terms of disease free survival (DFS) and results in reduced risk of lymphoedema at 5 years. |
Patients with early stage breast cancer and axillary nodal metastases on needle biopsy |
SVUH via via St Luke’s Radiation Oncology Network |
(opens in a new window)Click here |
Radiotherapy Trial |
Opening Soon |
FLAMINGO–01 |
To Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF). |
Patients with HER2/neu Positive with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy. |
SVUH |
TBD |
Medicinal Trial |
Opening Soon |